Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious disease focused biopharma company's lead molecule.

Skillington says that he "couldn't be happier" with the results, that he says will help "ramp up the discussions" with potential partners.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com